Document is current
Any future updates will be listed below
-
Authors
Bai, Xilong
Liu, Tingting
Li, Congge
Qiu, Caie
Ge, Xiaofan
Gou, Huili
Cai, Hongzhi
Yang, Liting
Wei, Sili
Yang, Wei
Li, Tianqing
-
Funding
Funding for this research was provided by:
Key Technologies Research and Development Program (2022YFA1103100)
Natural Science Foundation of Yunnan Province (202102AA100007, 202102AA100053 and YNWR-YLXZ-2020-015)
Major Basic Research Project of Natural Science Foundation of Yunnan Province (202203AC100011)
Spring City Plan the High-level Talent Promotion and Training Project of Kunming (Spring City Plan the High-level Talent Promotion and Training Project of Kunming)
Key Research Development Program of Shaanxi Province (2021SF-104)
Xi'an Talent Program Young Talents (Xi'an Talent Program Young Talents)
- License Information
-
More Information
Article History
Received: 5 December 2024
Accepted: 15 April 2025
First Online: 24 April 2025
Declarations
:
: All umbilical cord and PBMCs samples were taken after informed and written consent, and the study was approved by the Ethics Committee of Xi’an Gaoxin Hospital (Title is Umbilical cord harvesting for drug development of human umbilical cord mesenchymal stem cells. Approval number is GXYYEC-2019-003. Date of approval is May 8, 2019). The animal experiments were approved by the Institutional Animal Care and Use Committee of Kunming University of Science and Technology (The title is therapeutic value and application evaluation of mesenchymal stromal cells in a rodent model of autoimmune hepatitis. Approval number is PZWH-K2022-0014. Date of approval is Jun 16, 2022. The title is preclinical safety study of engineered mesenchymal stem cells. Approval number is PZWH-K2023-0041. Date of approval is March 18, 2023) and were performed in accordance with the Guide to the Care and Use of Laboratory Animals. The study adhered to the Declaration of Helsinki.
: Not applicable.
: The authors X. B., X. G., C. Q., H. G., S. W., T. L., W. Y., L. Y., and T. L. are employed by Xi’an ChaoYue Stem Cell Co., Ltd. and hold no stocks of the company. The other authors declare that they have no competing interests.
